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ABSTRACT
BACKGROUND: The diagnosis of cancer in Nigeria is 
often translated to mean an imminent death for the 
patient. This contrasts the situation in some developed 
settings where cancer survivorship and its management 
have evolved. Choriocarcinoma is a rare but curable 
tumour so; it became necessary to review cases of this 
curable cancer managed at a tertiary health center in a 
typical resourced-constrained setting.
METHODS: A retrospective analysis of consecutive 
choriocarcinoma cases managed at a tertiary hospital in 
Enugu, South-eastern Nigeria over a five year period. 
Data analysis was descriptive.
RESULTS: Five non-metastatic and 10 metastatic cases 
of choriocarcinoma were managed.  The mean age of 
patients was 33.6±9.1 years. All patients had vaginal 
bleeding with a mean duration of 4±5.19 months. The 
commonest predisposing factor and metastatic site were 
abortion (46.7%) and lungs (40.0%) respectively. The 
mean unit of blood transfusion during treatment was 
5.3±3.8 units. Eight patients (53.3%) died on admission 
while 7 (46.7%) were lost to follow-up during 
chemotherapy 20.0% or after chemotherapy (26.7%). 
CONCLUSION: The case fatality for choriocarcinoma 
and loss of patients to follow-up in Enugu, Nigeria were 
high. To shift from this situation of high mortality to that 
of survival, an improved follow-up of post-abortal 
patients and aggressive tracing of defaulters are 
recommended. 
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INTRODUCTION
The diagnosis of cancer in Nigeria is often translated by 
patients, relatives and caregivers to mean an imminent 
death for the victim. It is therefore not surprising that 
discussions on the long-term management of cancer 
1 
survivors, which has evolved in developed nations, are 
yet to develop in our environment. Because 
2
choriocarcinoma is generally viewed to be curable,  it is 
believed that a review of cases of this rare tumour 
managed at a tertiary center in a typical resourced-
constrained setting would serve as a platform upon 
which one reflects on the chances of survival from 
commoner and “non-curable” tumours in Nigeria and 
related countries. 
 Choriocarcinoma is a malignant form of the spectrum of 
diseases called Gestational trophoblastic diseases 
(GTD) which is derived from abnormal proliferation of 
2the gestational trophoblast.  The disease spectrum 
begins with the benign form called hydatidiform mole, 
through the locally metastatic invasive mole, to the 
malignant choriocarcinoma and placental site 
2
trophoblastic tumour.  Choriocarcinoma is a pure 
epithelial tumour that metastasizes widely through the 
3blood stream.  It has also been described as the 
commonest cancer involving the uterus which 
4 metastasizes to the lungs. Like other types of GTD, 
choriocarcinoma affects women of reproductive age 
group at a time when their social and economic 
5commitments are at the peak.  It is associated with 
pregnancy and may accompany or follow any type of 
pregnancy including molar pregnancy, term pregnancy, 
6abortions and ectopic pregnancies.  It is commoner in 
Africa and Asia but rare in European and North 
7
American populations.  In Nigeria, it constitutes 21.5% 
8
of all cases of GTD;  the second and fourth commonest 
9
genital malignancy in Ibadan, South west Nigeria,  and 
10
Maiduguri, North east Nigeria respectively.  According 
to the International Federation of Gynecology and 
11Obstetrics (FIGO),  choriocarcinoma is clinically 
categorized into four stages thus - Stage I is when the 
disease is confined to the uterus while stage II disease 
has spread to genital structure(s); stage III involves 
metastases to the lungs, while stage IV describes disease 
that has spread to other sites. Likewise, a modified WHO 
Prognostic scoring system based on eight risk factors is 
used to categorize the disease into low or high risk 
disease, and it has been shown that the high risk disease 
11
responds poorly to single agent chemotherapy.   
Choriocarcinoma is an unusual tumour in that it is very 
chemosensitive and curable in the majority of cases 
unlike most other malignancies - the low-risk and high-
risk types have cure rates of about 100% and 75% 
12
respectively.  Fortunately, the tumour also elaborates a 
marker called human chorionic gonadotropin (hCG) 
which assay in serum or urine is used for diagnosis, 
13
treatment monitoring and follow-up.  Nevertheless, 
despite these favourable characteristics of the disease, 
its treatment may not be very successful in resourced-
constrained settings including Nigeria, hence this study.
 MATERIALS AND METHODS 
The study was a retrospective analysis of consecutive 
cases of women managed for choriocarcinoma at the 
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University of Nigeria Teaching Hospital (UNTH) 
stEnugu, South east, Nigeria over a five year period of 1  
stJanuary 2002 to 31  December 2006.
A list of cases of choriocarcinoma was made from the 
admission register at the gynaecological ward of the 
hospital. The case folders were retrieved from the 
Records department of the hospital after necessary 
approvals. Information sought for include patients' age, 
parity, blood group, clinical features, and outcome of 
treatment. 
Data analysis was descriptive using Statistical Package 
for Social Sciences (SPSS) computer software version 
13.0 for windows [SPSS INC: Chicago Illinois]. Study 
results were presented using simple percentages and 
tables. 
Enugu town is the capital of Enugu state which is one of 
the five Igbo speaking states in the south east geo-
political zone of Nigeria. The state has a land area of 
2 
about 8000 km which is located within the West African 
rain forest region; and has 17 local government areas, 
14 most of which are rural. As at the end of the study 
period, the Enugu state had a population of 3,257,298 
15
with a female to male ratio of about 1:1.
The UNTH, Enugu is a government owned tertiary 
hospital located in the South east geo-political zone of 
Nigeria. The hospital offers specialist care to the 
residents of the state and beyond. During the period 
under review, it was essentially the only health 
institution within the state equipped with the personnel 
and some basic support services for the management of 
choriocarcinoma. Further details of the study area / 
16center have been described in a recent study.
 RESULTS 
There were 15 cases of choriocarcinoma and 3,495 
deliveries during the study period which gave a 
prevalence of 4.3 cases of choriocarcinoma per 1,000 
deliveries. Five (33.3%) cases were non-metastatic 
(FIGO Stage I) while the remaining 10 (66.7%) cases 
were metastatic. Out of the latter, 3 (30.0%) cases had 
metastasis to the lungs while another 3 (30.0%) had sub-
urethral metastasis. Further details of the FIGO clinical 
staging of the patients is shown in table 1.
Clinical presentation
The mean age of patients was 33.6 ± 9.1 years (range = 
 










I No metastasis 5 (33.3) 0 (0.0) 5 (100.0) 
II Anterior vaginal wall  1 (6.7) 1 (100.0) 0 (0.0) 
Sub-urethral 3 (20.0) 2 (66.7) 1 (33.3) 
III Lung only  3 (20.0) 3 (100.0) 0 (0.0) 
Lungs and sub-
urethral 
3 (20.0) 2 (66.7) 1 (33.3) 




Mild 2 (13.3) 0 (0.0) 2 (100.0) 
Moderate 6 (40.0) 1 (16.7) 5 (83.3) 
Severe 7 (46.7) 7 (100.0) 0 (0.0) 
 
Size of uterus 
(cm) 
10 - 12 7 (46.7) 3 (42.9) 4 (51.7) 
14 - 16 6 (40.0) 5 (83.3) 1 (16.7) 
18 - 20 2 (13.3) 0 (0.0) 2 (100.0) 
 
Pints of blood 
transfused 
0 2 (13.3) 0 (0.0) 2 (100.0) 
1 - 6 8 (53.3) 4 (50.0) 4 (50.0) 
7 - 12 5 (33.3)  4(80.0)  1 (20.0)
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18- 48). The median parity was 1 (range: = 0  6). Details 
of the patients' socio-demographic characteristics are 
shown in table 2. 
Table 2: Distribution of patients' socio 
demographic characteristics
All the patients presented with complaint of vaginal 
bleeding of varying duration with an average of 4 ± 5.19 
months (range = 1 - 18). The condition was preceded by 
term pregnancy in 4 patients (26.7%), abortion in 7 
patients (46.7%), and molar pregnancy in the remaining 
4 patients (26.7%). The interval between antecedent 
pregnancy and diagnosis of the condition was 1-6 
months in 8 patients (53.3%), 7 - 12 months in 1 patient 
(6.8%), and 1-2 years in 6 patients (40.0%). All the 
patients were anaemic on admission with majority 
(46.7%) of them having severe anaemia. The median 
packed cell volume (PCV) on admission was 21.0% 
(mean = 21.2±6.0%, range = 7 - 31). All patients had 
uterine enlargement of varying degree with a median 
uterine size of 14 weeks (range = 10-20). Details of the 
distribution of patients according to anaemia and uterine 
size categories are shown in table 1.
Investigations 
Urine pregnancy test (neat, and in dilution), 
abdominopelvic ultrasonography, chest radiography, 
full blood count, blood grouping, liver function test, and 
renal function test were done for all patients. 
Histological confirmation of diagnosis was carried out 
in 6 patients (40.0%), while elevated urine hCG were 
used for diagnosis in the remaining 9 patients (60.0%). 
Eleven patients (73.3%) belonged to blood group O 
+ve +ve
Rhesus D positive (O ), 2 (13.3%) were B , while 
+ve +ve 
blood groups A and AB had one patient (6.7%) each. 
None of the patients had Rh D negative blood group. 
Treatment 
All patients were admitted into the gynaecology ward 
during evaluation and treatment. The mean duration of 
admission was 63.8±32.9 days (range = 20-120). A 
majority (86.7%) of the patients received transfusion of 
typed and screened blood depending on their state of 
anaemia. In all, eighty units of blood were transfused to 
these patients and the median units of blood transfused 
per patient was 5 (mean = 5.3± 3.8 units, range = 0 - 12).
Chemotherapy was initiated for all patients following 
diagnosis. Three patients (20.0%) received 
monotherapy of methotrexate only, 11 (73.3%) received 
combination therapy of methotrexate, actinomycin-D, 
and cyclophosphamide, while 1 patient (6.7%) received 
combination therapy of cisplatinum and vincristin. 
Outcome 
Eight patients (53.3%) died in the ward after a median 
cumulative duration of admission of 66.9 days (mean = 
65.5 ± 39.7 days, range = 20-120). The cause of death in 
each case was haemorrhagic shock from uterine 
bleeding. The remaining 7 patients (46.7%) were lost to 
follow-up either in between courses of chemotherapy (3 
patients) or after completing their courses of 
chemotherapy (4 patients). Details are contained in table 
3.
DISCUSSION
The mean age for the occurrence of choriocarcinoma of 
33.6 years was similar to 30.6 years reported from Port-
17Harcourt South-southern Nigeria.  It has been 
documented that incidence of choriocarcinoma 
increased with age and was 5-15 times higher in women 
aged 40 years and above when compared to younger 
18 
women. However, the reverse was almost the case in 
this study where the prevalence of the disease was about 
3 times higher in women less than 40 years when 
compared to older women (table 2). Furthermore, this 
th
study shows that the disorder was commoner in the 4  
 
Patients variables  Variable sub-groups Frequency (%) 
Age groups (years) 
 
20 or less 2 (13.3) 
21 - 30 3 (20.0) 
31 - 40 7 (46.7) 
41 - 50 3 (20.0) 
Age range (years) 
 
< 40 11 (73.3) 
>= 40 4 (26.7) 
Marital status 
 
Married 13 (86.7) 
Single 2 (13.3) 
Parity groups 
 
>= 5 4 (26.7) 
2 - 4                                           3 (20.0)
   1                                             6 (40.0)
   
   0                                              2 (13.3)














(n = 5) 
4 (80.0) 1 (10.0) 0 (0.0) 0.0 20.0 
Metastatic 
(n = 10) 
0 (0.0) 2 (20.0) 8 (80.0) 80.0 100.0 
Total 
(n = 15) 
4 (26.7) 3 (20.0) 8 (53.3) 53.3 73.3 
*: Assume all defaulted patients died 
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rd
decade of life as against the 3  decade of life reported 
19
from Northern Nigeria.  This difference in reported 
peak age may be related to the fact that women in 
southern Nigeria tend to marry later than their 
counterparts in the Northern part of the country. 
Furthermore, unlike the study from Benin Nigeria which 
found that most cases of choriocarcinoma were 
20
preceded by normal pregnancy,  our study showed that 
the commonest predisposition to choriocarcinoma was 
abortion while the least was molar pregnancy. Likewise, 
these findings did not conform to the usual teaching that 
hydatidiform mole was the antecedent pregnancy in up 
3,6to 50% of cases of choriocarcinoma.  However, in the 
absence of histological examination of abortuses, it is 
possible that some cases reported as abortion by patients 
11in this study could have been molar pregnancies.  On 
the other hand, it is equally likely that the traditional 
teaching on the  antecedent  pregnancy to  
choriocarcinoma, may not represent the true situation in 
Nigeria. Therefore, considering the small sample size in 
this study, a large scaled multi-center prospective study 
on choriocarcinoma is highly necessary to generate the 
true epidemiology of the disorder in our environment. 
Urine pregnancy test was used for diagnosis and follow-
up in the study because the more sensitive assay for 
serum B-hCG was not available in the center. This 
situation may not be different for some other referral 
centers in Nigeria. For instance, a case report from 
Northern Nigeria used urine pregnancy test in the 
21 management of metastatic choriocarcinoma. Also, 
another report on GTD from Ilorin, Nigeria noted that 
urine pregnancy test in dilution was used for patient 
diagnosis and follow-up because the facility for 
22quantitative B-hCG assay was lacking.  Nevertheless, 
though serum B-hCG is the gold standard for diagnosis 
and follow-up of malignant GTD, concurrent use of 
urine and serum hCG assay has been recommended so as 
to rule out false positivity inherent with serum hCG 
which is due to the presence of heterophilic antibodies in 
23
some individuals.  
Interestingly, none of the women identified in the study 
had a rhesus negative blood and our extensive literature 
search did not reveal a report of GTD in a rhesus 
negative woman. This raises the possibility that rhesus 
negativity may be protective against the disease and 
calls for further study. As expected, the commonest 
metastatic site was the lungs however; it is interesting to 
note that sub-urethral metastasis was equally common in 
this study  it is therefore important that specialist 
involved in choriocarcinoma case management should 
specifically examine for the metastasis because it is a 
common site of blood loss.  
The haemorrhagic nature of the illness was supported by 
our finding that all patients were anaemic at presentation 
with an average blood transfusion per patient of 5 units. 
It is therefore obvious that the management of 
choriocarcinoma should be carried out in a specialist 
center with functional blood banking services. The study 
also suggests a trend where patients that were severely 
anaemic on presentation were likely to die while those 
with mild or moderate degrees anaemia were likely to 
default from treatment (table 1). It therefore calls for a 
more aggressive management of severely anaemic cases 
so as to reduce mortality; as well as a scaled-up in the 
counselling and monitoring of mild to moderate 
anaemic cases to minimize default from follow up.
The case fatality of 53.3% in this study is very high and 
is not in line with the global view that choriocarcinoma 
is curable in 75 - 100% of cases depending on the 
12severity of the disease.  Also, it is likely that the 3 
patients lost to follow-up during chemotherapy died, 
which would increase the case fatality to 73.3%. This 
finding may not be surprising because an earlier report 
from Enugu, Nigeria had shown that choriocarcinoma 
was the second leading cause of  gynaecologic 
24mortality.  Furthermore, it has been noted that the 
marked improvement in the outcome of treatment of 
choriocarcinoma was due to a combination of three 
factors thus: earlier case diagnosis, the ability to 
precisely measure hCG, and the availability of effective 
11chemotherapy.  Unfortunately, these conditions are still 
not optimally developed in the study area so, late 
presentation and diagnoses of cases as well as sub-
optimal management were possible contributors to the 
high case fatality recorded in this study. The situation is 
worsened by the cost of choriocarcinoma treatment 
especially the direct cost of long hospital stay, multiple 
blood transfusion, and chemotherapy which may be 
related to the magnitude of loss to follow-up identified 
in this study.
This study was limited by its retrospective nature and the 
attendant reliance on case notes. Also, the defaulters 
from treatment and follow up obviously affected the 
assessment of the true case fatality. Nevertheless, the 
study is the first documented analysis on 
choriocarcinoma from the study area and has identified 
areas of interest that may stimulate further research in 
the subject. Prospective studies coupled with an 
aggressive tracing of defaulters, with a view to 
encouraging compliance and identifying reasons for 
defaulting, are highly encouraged. 
In conclusion, deaths due to choriocarcinoma and loss of 
cases to follow-up in Enugu, South-eastern Nigeria were 
high within the period reviewed, and the current 
situation might not be different considering the 
worsening health care system and poverty in Nigeria. To 
shift from the situation of high mortality to that of 
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survival, which is the expected trend in cancer 
management, an improved follow-up of post-abortal 
patients, review of local management protocols, 
aggressive tracing of defaulters are recommended. Most 
importantly, because of the high financial cost of 
choriocarcinoma treatment, free or subsidized treatment 
by government / non-governmental agencies will 
improve patients' compliance and reduce loss to follow-
up. Furthermore, in the spirit of “Global Partnership for 
Development” being propagated by the United Nations' 
Millennium Development Goals initiative, it is hoped 
that established gynaecologic oncology centers in high 
resource countries should assist training institutions in 
under-resourced countries to develop effective and 
sustainable gynaecologic oncology services.  
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